CCP allows Citi Pharma to acquire Pakheim

The Competition Commission of Pakistan has cleared Citi Pharma Limited’s proposed purchase of all shares in Pakheim International Pharma, finding no competition concerns, Business Recorder reported. Citi Pharma disclosed the approval in a material information notice filed with the Pakistan Stock Exchange on October 16, after receiving the CCP’s order dated October 9, 2026.

The transaction is to proceed under the share purchase agreement signed on May 6, 2026, and remains subject to the required legal, regulatory and other formalities. Citi Pharma said it will issue further disclosures as relevant milestones are completed, so the reported approval is one step in the acquisition process rather than confirmation that the deal has closed. The development relates directly to Citi Pharma and the pharmaceuticals sector.